Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKesson
Medtronic
Express Scripts
Merck
Baxter
Moodys

Last Updated: December 13, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020705

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

NDA 020705 describes RESCRIPTOR, which is a drug marketed by Viiv Hlthcare and is included in one NDA. It is available from one supplier. There is one patent protecting this drug. Additional details are available on the RESCRIPTOR profile page.

The generic ingredient in RESCRIPTOR is delavirdine mesylate. One supplier is listed for this compound. Additional details are available on the delavirdine mesylate profile page.
Summary for 020705
Tradename:RESCRIPTOR
Applicant:Viiv Hlthcare
Ingredient:delavirdine mesylate
Patents:1
Formulation / Manufacturing:see details
Pharmacology for NDA: 020705
Medical Subject Heading (MeSH) Categories for 020705
Suppliers and Packaging for NDA: 020705
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
RESCRIPTOR delavirdine mesylate TABLET;ORAL 020705 NDA ViiV Healthcare Company 49702-225 49702-225-17 180 TABLET in 1 BOTTLE (49702-225-17)

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;ORALStrength100MG
Approval Date:Apr 4, 1997TE:RLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength200MG
Approval Date:Jul 14, 1999TE:RLD:Yes
Patent:  Start TrialPatent Expiration:Jun 7, 2019Product Flag?Substance Flag?Delist Request?

Expired US Patents for NDA 020705

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Viiv Hlthcare RESCRIPTOR delavirdine mesylate TABLET;ORAL 020705-001 Apr 4, 1997   Start Trial   Start Trial
Viiv Hlthcare RESCRIPTOR delavirdine mesylate TABLET;ORAL 020705-002 Jul 14, 1999   Start Trial   Start Trial
Viiv Hlthcare RESCRIPTOR delavirdine mesylate TABLET;ORAL 020705-002 Jul 14, 1999   Start Trial   Start Trial
Viiv Hlthcare RESCRIPTOR delavirdine mesylate TABLET;ORAL 020705-001 Apr 4, 1997   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
Baxter
Colorcon
Mallinckrodt
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.